How to buy Cumberland Pharmaceuticals stock

Cumberland Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Cumberland Pharmaceuticals shares (CPIX) are listed on the NASDAQ and all prices are listed in US Dollars. Cumberland Pharmaceuticals employs 90 staff and has a trailing 12-month revenue of around 0.00.

Cumberland Pharmaceuticals share price

Use our graph to track the performance of CPIX stocks over time.

Cumberland Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$2.77 - $4.14
50-day moving average	$3.09
200-day moving average	$3.11
Wall St. target price	$8.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.29

Buy Cumberland Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cumberland Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cumberland Pharmaceuticals Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Cumberland Pharmaceuticals under- or over-valued?

Valuing Cumberland Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cumberland Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cumberland Pharmaceuticals's EBITDA

Cumberland Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.8 million.

The EBITDA is a measure of a Cumberland Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Cumberland Pharmaceuticals financials

Revenue TTM	$37.4 million
Gross profit TTM	$28.8 million
Return on assets TTM	-3.97%
Return on equity TTM	-13.53%
Profit margin	-8.92%
Book value	$3.14
Market capitalisation	$40.7 million

TTM: trailing 12 months

Shorting Cumberland Pharmaceuticals shares

There are currently 106,716 Cumberland Pharmaceuticals shares held short by investors – that's known as Cumberland Pharmaceuticals's "short interest". This figure is 5.4% up from 101,286 last month.

There are a few different ways that this level of interest in shorting Cumberland Pharmaceuticals shares can be evaluated.

Cumberland Pharmaceuticals's "short interest ratio" (SIR)

Cumberland Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Cumberland Pharmaceuticals shares currently shorted divided by the average quantity of Cumberland Pharmaceuticals shares traded daily (recently around 29398.347107438). Cumberland Pharmaceuticals's SIR currently stands at 3.63. In other words for every 100,000 Cumberland Pharmaceuticals shares traded daily on the market, roughly 3630 shares are currently held short.

However Cumberland Pharmaceuticals's short interest can also be evaluated against the total number of Cumberland Pharmaceuticals shares, or, against the total number of tradable Cumberland Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cumberland Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cumberland Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0127% of the tradable shares (for every 100,000 tradable Cumberland Pharmaceuticals shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cumberland Pharmaceuticals.

Find out more about how you can short Cumberland Pharmaceuticals stock.

Cumberland Pharmaceuticals share dividends

We're not expecting Cumberland Pharmaceuticals to pay a dividend over the next 12 months.

Have Cumberland Pharmaceuticals's shares ever split?

Cumberland Pharmaceuticals's shares were split on a 2:1 basis on 5 July 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cumberland Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cumberland Pharmaceuticals shares which in turn could have impacted Cumberland Pharmaceuticals's share price.

Cumberland Pharmaceuticals share price volatility

Over the last 12 months, Cumberland Pharmaceuticals's shares have ranged in value from as little as $2.77 up to $4.14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cumberland Pharmaceuticals's is 0.2752. This would suggest that Cumberland Pharmaceuticals's shares are less volatile than average (for this exchange).

Cumberland Pharmaceuticals overview

Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc.

Frequently asked questions

• What percentage of Cumberland Pharmaceuticals is owned by insiders or institutions?

  Currently 43.6% of Cumberland Pharmaceuticals shares are held by insiders and 26.214% by institutions.

• How many people work for Cumberland Pharmaceuticals?

  Latest data suggests 90 work at Cumberland Pharmaceuticals.

• When does the fiscal year end for Cumberland Pharmaceuticals?

  Cumberland Pharmaceuticals's fiscal year ends in December.

• Where is Cumberland Pharmaceuticals based?

  Cumberland Pharmaceuticals's address is: 2525 West End Avenue, Nashville, TN, United States, 37203

• What is Cumberland Pharmaceuticals's ISIN number?

  Cumberland Pharmaceuticals's international securities identification number is: US2307701092

• What is Cumberland Pharmaceuticals's CUSIP number?

  Cumberland Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 230770109